Jonathan Goldin

1996–2025 年に発表

115
論文数
22,857
被引用数
73
h 指数
110
i10 指数

被引用数

Jonathan Goldin の年別被引用数1982 年: 被引用 1 件1990 年: 被引用 1 件1991 年: 被引用 1 件1994 年: 被引用 2 件1997 年: 被引用 2 件1998 年: 被引用 5 件1999 年: 被引用 11 件2000 年: 被引用 15 件2001 年: 被引用 42 件2002 年: 被引用 55 件2003 年: 被引用 84 件2004 年: 被引用 93 件2005 年: 被引用 120 件2006 年: 被引用 101 件2007 年: 被引用 149 件2008 年: 被引用 175 件2009 年: 被引用 167 件2010 年: 被引用 127 件2011 年: 被引用 166 件2012 年: 被引用 166 件2013 年: 被引用 146 件2014 年: 被引用 148 件2015 年: 被引用 152 件2016 年: 被引用 169 件2017 年: 被引用 152 件2018 年: 被引用 188 件2019 年: 被引用 663 件2020 年: 被引用 943 件2021 年: 被引用 844 件2022 年: 被引用 628 件2023 年: 被引用 465 件2024 年: 被引用 710 件2025 年: 被引用 390 件2026 年: 被引用 11 件1983〜1989 年は被引用が無いため表示していません1992〜1993 年は被引用が無いため表示していません1995〜1996 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,515 件、この内訳の 26.9%イギリス: 引用元論文 752 件、この内訳の 8%ドイツ: 引用元論文 618 件、この内訳の 6.6%イタリア: 引用元論文 585 件、この内訳の 6.2%中国: 引用元論文 518 件、この内訳の 5.5%フランス: 引用元論文 437 件、この内訳の 4.7%カナダ: 引用元論文 411 件、この内訳の 4.4%オランダ: 引用元論文 397 件、この内訳の 4.2%日本: 引用元論文 322 件、この内訳の 3.4%スイス: 引用元論文 240 件、この内訳の 2.6%スペイン: 引用元論文 204 件、この内訳の 2.2%オーストラリア: 引用元論文 202 件、この内訳の 2.2%
0%26.9%その他 23.1%

分野

  • Medicine89.6%
  • Biochemistry, Genetics and Molecular Biology3.5%
  • Computer Science2.5%
  • Engineering1.5%
  • Physics and Astronomy0.8%
  • Immunology and Microbiology0.5%
  • その他1.6%

トピック

  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis8.6%
  • Systemic Sclerosis and Related Diseases6.1%
  • Lung Cancer Diagnosis and Treatment5.1%
  • Radiomics and Machine Learning in Medical Imaging4.9%
  • COVID-19 diagnosis using AI3.5%
  • Chronic Obstructive Pulmonary Disease (COPD) Research3.2%
  • その他68.6%

共著者

全論文

検索で開く
  1. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mette Mogensen, Anne Braae Olesen, Yannick Allanore, J. Henes, Ulf Müller‐Ladner, Gabriela Riemekasten, Alla Skapenko, Panayiotis G. Vlachoyiannopoulos, Emese Kiss, Tünde Minier, Lorenzo Beretta, Elisa Gremese, Marco Matucci‐Cerinic, Gabriele Valentini, Yoshihide Asano, Tatsuya Atsumi, Hironobu Ihn, Tomonori Ishii, Osamu Ishikawa, Masataka Kuwana, Yoshihito Shima, Hiroki Takahashi, Kazuhiko Takehara, Yoshiya Tanaka, Yoshioki Yamasaki, Loreta Bukauskienė, İrena Butrimienė, Gabriel Medrano Ramírez, César Ramos-Remus, Tatiana Sofía Rodríguez Reyna, Jeska de Vries‐Bouwstra, Jacob M. van Laar, Bogdan Batko, Sławomir Jeka, Eugeniusz J. Kucharz, Maria Majdan, Marzena Olesińska, Żaneta Smoleńska, José Delgado Alves, María José Santos, C. Mihai, Simona Rednic, Ivan Castellvi Barranco, Francisco Longo, C Simeόn Aznar, Patrícia Carreira, Oliver Distler, Ulrich A. Walker, Emma Derrett‐Smith, Bridget Griffiths, Neil D McKay, Christopher P. Denton, Jacob Aelion, Michael Borofsky, Roy Fleischmann, Joseph Z. Forstot, Daniel E. Furst, Suzanne Kafaja, Mahmuda Khan, Dinesh Khanna, Michael Kohen, Richard W. Martin, Fabian Mendoza-Ballesteros, Alireza Nami, Shirley Pang, Grissel Ríos, Robert W. Simms, Keith M. Sullivan, Virginia Steen - The Lancet Respiratory Medicine 2020 被引用: 652

  2. The National Lung Screening Trial: Overview and Study Design

    著者: , , , , , , , , , , , , , , , , , , - Radiology 2010 被引用: 1,275

  3. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Richard T. Meehan, Arthur C. Theodore, Robert W. Simms, Suncica Volkov, Dean E. Schraufnagel, Mary Beth Scholand, Tracy Frech, Jerry A. Molitor, Kristin B. Highland, Charles A. Read, Marvin J. Fritzler, Grace Hyun J. Kim, Chi‐Hong Tseng, Robert M. Elashoff - The Lancet Respiratory Medicine 2016 被引用: 1,062

  4. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper

    著者: , , , , , , , , , , , , , , , , - The Lancet Respiratory Medicine 2017 被引用: 1,022

  5. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial

    著者: , , , , , , , , , , , , , , , , - The Lancet Respiratory Medicine 2019 被引用: 286

  6. Cyclophosphamide versus Placebo in Scleroderma Lung Disease

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mark L. Metersky - New England Journal of Medicine 2006 被引用: 1,667

  7. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Richard M. Silver, Leroy Griffing, Jan Storek, Sharon LeClercq, Richard Brasington, Mary Ellen Csuka, Christopher Bredeson, Carolyn A. Keever-Taylor, Robyn T. Domsic, M. Bashar Kahaleh, Thomas A. Medsger, Daniel E. Furst - New England Journal of Medicine 2018 被引用: 589

  8. The Role of Chest Imaging in Patient Management During the COVID-19 Pandemic

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - CHEST Journal 2020 被引用: 1,304

  9. SPIROMICS Protocol for Multicenter Quantitative Computed Tomography to Phenotype the Lungs

    著者: , , , , , , , , , , , , , , , , - American Journal of Respiratory and Critical Care Medicine 2016 被引用: 255

  10. Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial

    著者: , , , , , , , , , , , , , , , , , , , - American Journal of Respiratory and Critical Care Medicine 2024 被引用: 65

  11. Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis

    著者: , , , , , , , , , , , , , , , , , , , , , , , - American Journal of Respiratory and Critical Care Medicine 2018 被引用: 148

  12. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)

    著者: , , , , , , , , , , , , , , , , - BMJ Open Respiratory Research 2021 被引用: 53

  13. Translating AI to Clinical Practice: Overcoming Data Shift with Explainability

    著者: , , , , , , , , - Radiographics 2023 被引用: 56

  14. Tocilizumab Prevents Progression of Early Systemic Sclerosis–Associated Interstitial Lung Disease

    著者: , , , , , , , , - Arthritis & Rheumatology 2021 被引用: 191

  15. Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis–Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial

    著者: , , , , , , , , , - American Journal of Respiratory and Critical Care Medicine 2021 被引用: 132

  16. Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on ‘Feels, Functions, Survives’. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jessica Shore, Marlies Wijsenbeek, Robert S. Brown, Daniel Grogan, Dorothy Ivey, Patrycja Golińska, Banu A. Karimi-Shah, Fernando J. Martínez - American Journal of Respiratory and Critical Care Medicine 2024 被引用: 76

  17. Coronary-Artery Calcification in Young Adults with End-Stage Renal Disease Who Are Undergoing Dialysis

    著者: , , , , , , , , , , , - New England Journal of Medicine 2000 被引用: 2,504

  18. CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a Position Paper from the Fleischner society

    著者: , , , , , - The Lancet Respiratory Medicine 2015 被引用: 185

  19. Comparison of the Quantitative CT Imaging Biomarkers of Idiopathic Pulmonary Fibrosis at Baseline and Early Change with an Interval of 7 Months

    著者: , , , , , , , , , - Academic Radiology 2014 被引用: 127

  20. Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib

    著者: , , , , , , , , , , , , , , - Neuro-Oncology 2021 被引用: 63

  21. Assessment of Coronary Artery Disease by Cardiac Computed Tomography

    著者: , , , , , , , , , , , - Circulation 2006 被引用: 1,399

  22. Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis–Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II

    著者: , , , , , , , , , , - Arthritis & Rheumatology 2017 被引用: 159

  23. High-resolution CT phenotypes in pulmonary sarcoidosis: a multinational Delphi consensus study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Antje Prasse, Antonietta Mazzei, António Morais, Ashu Seith Bhalla, Belén del Río, Bhavin Jankharia, Brett M. Elicker, Carlos A.C. Pereira, Catherine Biegelman-Aubry, Charles S. White, Claudia Ravaglia, Connie C. W. Hsia, Cornelia Schaefer‐Prokop, David Launay, Deepak Talwar, Diego Castillo, Divya Patel, Dominique Israël‐Biet, Dominique Valeyre, E. James Britt, Elena Bargagli, Elisabeth Bendstrup, Elliott D. Crouser, Esther J. Nossent, Eugeny Shmelev, Eva Carmona Porquera, Francesco Bonella, Fleur Cohen‐Aubart, Florence Jeny, Giovanni Ferrara, Gong Yong Jin, Hasti Robbie, Helmut Prosch, Hiromitsu Sumikawa, Ho Ling-Pei, Ho Yun Lee, Irina Strâmbu, Ivette Buendía-Roldán, Jan Grutters, Jay H. Ryu, Jeff Swigris, Jelle Miedema, Jin Mo Goo, Joseph Barnett, Johny Verschakelen, Jonathan Goldin, Joon Beom Seo, Juan Ignacio Enghelmayer, Juan Mañá, Juergen Behr, Karen Patterson, Κατερίνα Αντωνίου, Kevin M. Brown, Kiminori Fujimoto, Laurent Savale, Lisa A. Maier, Luca Richeldi, Manuel L. Ribeiro Neto, Marc Humbert, Marc A. Judson, Marcel Veltkamp, Margaret Wilsher, María Molina‐Molina, María Otaola, Marie‐Pierre Revel, Mario Silva, Marjolein Drent, Mark L. Schiebler, Marlies Wijsenbeek-Lourens, Martina Bonifazi ほか 50 名 - The Lancet Respiratory Medicine 2023 被引用: 67

  24. A Randomized Study of Endobronchial Valves for Advanced Emphysema

    著者: , , , , , , , , , - New England Journal of Medicine 2010 被引用: 848